Finally, we did not observe a substantial change in angiogenesis in the skin when we elevated circulating leptin in non-tumour-bearing mice, consistent with the view that, in SCCs, leptin is not the driver but rather the consequence of the elevated angiogenesis that occurs during malignant progression. This evidence concerns the gene LEP and neoplasm.